Secukinumab treatment and vaccination efficacy.

Mohammed, A; Singh, R; Feldman, S R

Mohammed, A; Singh, R; Feldman, S R.

Mohammed A; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Singh R; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Feldman SR; Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Clin Exp Dermatol ; 47(4): 750-751, 2022 04.

Article in English | MEDLINE | ID: covidwho-1506449

Subject(s)

Antibodies, Monoclonal, Humanized; Psoriasis; Antibodies, Monoclonal, Humanized/therapeutic use; Double-Blind Method; Humans; Psoriasis/drug therapy; Severity of Illness Index; Treatment Outcome; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Psoriasis / Antibodies, Monoclonal, Humanized Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Clin Exp Dermatol Year: 2022 Document Type: Article Affiliation country: Ced.15004

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google